Moderna, a leader in mRNA technology, has faced increasing scrutiny over its vaccine pricing and distribution strategies. The backlash has prompted the company to reassess its financial commitments to ongoing trials. This shift could impact not only Moderna’s future projects but also the broader landscape of vaccine innovation. Stakeholders are closely monitoring how this decision will affect public trust and health outcomes. 🌍💊